

Eur J Clin Chem Clin Biochem  
1995; 33:497–501

© 1995 Walter de Gruyter & Co.  
Berlin · New York

## An Automated Enzymatic Inulin Assay, Capable of Full Sinistrin Hydrolysis<sup>1)</sup>

By Charles P. R. Soper<sup>1</sup>, Michael R. Bending<sup>1</sup> and Jeffrey L. Barron<sup>2</sup>

<sup>1</sup> Renal Unit

<sup>2</sup> Chemical Pathology Department

St. Helier Hospital, Carshalton, Surrey, United Kingdom

(Received March 1/May 23, 1995)

**Summary:** Renal inulin clearance remains the standard by which other methods of measuring glomerular filtration rate are judged. A fully automated enzymatic assay capable of use with linear configuration inulin was recently published (Summerfield AL, et al. Clin Chem 1993; 39:2333–7). Sinistrin, a readily soluble preparation of polyfructan with side branching, is more suitable for clinical use and far more widely used in Europe. By modifying the incubation phase of samples with inulinase, incorporating a kinetic modification to the method of fructose analysis, and increasing the buffer strengths, we report a fully automated system, with minimal sample prehandling capable of complete sinistrin hydrolysis, and adapted for use on the Cobas Mira.

### Introduction

The measurement of inulin clearance as a marker of glomerular filtration rate provides the most accurate assessment of renal function. It is subject neither to extra renal metabolism, nor tubular handling, not bound by plasma proteins and capable of free passage through the glomerular basement membrane (1).

Its clinical use has been restricted by several difficulties. Firstly, the insolubility of standard inulin (linear configuration (1,2-linked) polyfructan) renders its use for patient injection difficult. Secondly, the acid hydrolysis of inulin prior to assaying liberated fructose requires considerable laboratory time, especially when concentrated and corrosive reagents are used for the additional purpose of deproteination. Finally colorimetric determination of fructose is not specific (2).

Recent modifications have incorporated the use of an enzymatic assay for fructose, either to the endpoint of substrate consumption, (using *Bergmeyer's* original combination of hexokinase, glucose-6-phosphate dehydrogenase and phosphoglucose isomerase) (3) or similar combinations (4), or more suitable for automation a kinetic assay based on sorbitol dehydrogenase (5)<sup>2)</sup>.


The use of commercially available synergistic combination of exo- and endo-inulinases<sup>2)</sup> has enabled a fully automated enzymatic assay (6). Our own trials of this method worked well with linear configuration inulin, once adapted to employ a kinetic assay for fructose. This adaptation is more suitable to a reaction which results in a small free energy change, leaving a substantial quantity of substrate in equilibrium with product. This modification has also recently been reported by the same group (7).

Sinistrin is a branched polyfructan first reported by *Schmeideberg* in 1879 (see fig. 1). Its natural source is as an energy storage compound in the bulb of the North

drogenase and phosphoglucose isomerase) (3) or similar combinations (4), or more suitable for automation a kinetic assay based on sorbitol dehydrogenase (5)<sup>2)</sup>.

<sup>2)</sup> Enzymes  
Novozym 230, a synergistic combination of inulinases:  
Exoinulinase:  
2,1- $\beta$ -D-Fructan fructanhydrolase EC 3.2.1.7  
Endoinulinases:  
Fructan- $\beta$ -fructosidase EC 3.2.1.80  
Indicator reaction catalyzed by:  
Sorbitol dehydrogenase EC 1.1.1.14.

<sup>1)</sup> This work was supported by a grant from the St Helier Research Trust Fund.



**Fig. 1** The structure of sinistrin, consisting of a linear 1,2-linked  $\beta$ -D-fructose polymer backbone with two or more 2,6-linked levanbiose side chains.

African root vegetable Red Squill, *Urginea maritima*. Its greater solubility allows far greater ease of handling and preparation for injection for clearance studies. Its degree of polymerisation, consequent relative molecular mass, and equivalent maximum radius from hydrodynamic studies (8) indicate a satisfactory permeability through the glomerular basement membrane, confirmed in subsequent clinical studies (9).

Sinistrin has proved considerably less amenable to enzymatic cleavage than linear inulin, we report a fully automated method capable of complete sinistrin hydrolysis.

## Materials and Methods

### Specimens

Plasma samples were taken as part of inulin infusion clearance examinations from healthy volunteers, its use has already been well described (10, 11). This method of analysis of inulin clearance is more suitable in patients with normal or high glomerular filtration rates such as the diabetic hyperfiltering patients we are studying, being less prone to errors from delay to steady state inulin concentration, and delayed equilibration with muscle and fascial tissue compartments. It entails the administration of a bolus dose of sinistrin proportionate to volume of distribution, and a continuous infusion at a rate anticipated to bring the serum steady state concentration to a predetermined target, calculated from previous estimates of clearance. Two samples are taken from the contralateral arm of semirecumbent subjects 2 h after commencement of the infusion. Together with a sample of the infusate these are analysed

for fructan content. Confirmation of steady state is sought by comparison of the 110 with 120 min polyfructan concentration.

### Reagents

Novozym 230<sup>2</sup>), a synergistic combination of inulinases (EC 3.2.1.7), with reported activity 1.8 MU/l, was obtained as a liquid concentrate from Novo Nordisk Enzyme Process Division. Sorbitol dehydrogenase (EC 1.1.1.14) as lyophilisate, preweighed 2 mg NADH vials, crystalline fructose, and three natural source inulin preparations (*Dahlia* Tuber, *Dahlia variabilis*, Chicory Root, *Cichorium intybus*, and Jerusalem Artichoke, *Helianthus tuberosus*) were obtained from Sigma Chemical Co. Ltd. (Poole, Dorset). Sinistrin (Inutest<sup>TM</sup>) was obtained from Laevosan-Gesellschaft, (Linz, Austria) in pharmaceutical grade vials for clinical use.

### Methods

We adapted the previously described method (6) for use on a Cobas Mira (Roche Diagnostic Systems, Welwyn, UK), incorporating a 1250 s predilution phase, a shorter path length for colorimetry, based on a kinetic analysis of the conversion of fructose to sorbitol, and two fructose standards for calibration with each run. The Mira programme is given in table 1.

Serum samples were stored at 4 °C for up to one week, or frozen and kept at -20 °C for up to 3 months. Urine and infusate samples were diluted twenty-fold in radioimmunoassay grade bovine serum albumin, 40 g/l before the assay.

A 150  $\mu$ l aliquot of Novozym 230 was diluted in 5 ml of 500 mmol/l sodium dihydrogen phosphate buffer at pH 4.5 to form the dilution solution. The final concentration of the inulinases being 40.5 kU/l. The sorbitol dehydrogenase was dissolved in 1 mol/l hydroxyethyl piperazineethanesulphonic acid (HEPES) buffer, pH 7.7, at 4 kU/l. The final reaction concentration being 0.53 units in

**Tab. 1** Cobas Mira Programme (for detailed explanation see the manufacturer's instructions):

Test INU (Inulinases present)	Test INA (Inulinases Absent)
Measurement Mode: Absorb Reaction Mode: D-R-S Calibration Mode: Slope Avg Reagent Blank: Reag/Sol Cleaner: No	Measurement Mode: Absorb Reaction Mode: D-R-S Calibration Mode: Slope Avg Reagent Blank: Reag/Sol Cleaner: No
Wavelength: 340 nm Decimal Posn: 1 Unit: mg/l	Wavelength: 340 nm Decimal Posn: 1 Unit: mg/l
Analysis Dilution Name: INI Factor: 4.00 Time: 1250 s Std: Factor	Analysis Dilution Name: INO Factor: 4.00 Time: No Std: Factor
Sample Cycle: 1 Volume: 50.0 µl Dilution Name: H <sub>2</sub> O Volume: 15.0 µl	Sample Cycle: 1 Volume: 50.0 µl Dilution Name: H <sub>2</sub> O Volume: 15.0 µl
Reagent Cycle: 1 Volume: 133 µl	Reagent Cycle: 1 Volume: 133 µl
Reac. Direction: Decrease Check: On Convers. Factor: 1.00000 Offset: 0.00000	Reac. Direction: Decrease Check: On Convers. Factor: 1.00000 Offset: 0.00000
Test Range Low: 0.0 mg/l High: 400.0 mg/l Number Of Steps: 1 Calc. Step A: Endpoint Readings First: 4 Last: 19	Test Range Low: 0.0 mg/l High: 100.0 mg/l Number Of Steps: 1 Calc. Step A: Endpoint Readings First: 4 Last: 19
Calibration Interval: Each Run Blank Sol-Pos: 7	Calibration Interval: Each Run Blank Sol-Pos: 8
Standard Pos: 1 Std-1; 200 mg/l Std-2; 200 mg/l Deviation: 1.5%	Standard Pos: 1 Std-1; 200 mg/l Std-2; 200 mg/l Deviation: 1.5%
Ratios	Racks Reagent 10
TING	Rack Posn:
Test	1 INI*
A: INU	2 INU
B: INI*	3 INO**
Decimal Posn: 1	4 INA
Unit: mg/l	
Formula A-B	
Factor: 1.0	

\* INI = Diluent for INU (with inulinases)

\*\* INO = Diluent for INA (no inulinases)

198 µl. A sample of 6 ml of this preparation was added to a 2 mg vial of NADH to form the reagent solution. This ensured blank absorbance readings of 1.0 to 1.2 at 340 nm. The final reaction concentration of NADH is 44 µg in 198 µl.

The volume of sample taken by the Mira is approximately 80 µl for predilution 1 in 4 with the inulinase solution. Incubation at 37 °C follows for nearly 21 min, 50 cycles on the Mira. From this a 50 µl aliquot was mixed with 133 µl of reagent solution. Colorimetry followed from the 4th to the 19th subsequent cycles.

A separate run was performed on each sample with and without Novozym in the diluent buffer. This enables a separate determination of the free fructose content prior to polyfructan hydrolysis. From the two runs the inulin or sinistrin content may be calculated. Complete assay time for inulin and free fructose concentration from 15 samples amounts to 38 min. Two 200 mg/l fructose standards in bovine serum albumin were used as calibrators for each run. Blanks contained 150 µl of the respective programme diluent, and 50 µl sodium dihydrogen phosphate buffer.

When stored at 4 °C, sorbitol dehydrogenase retains its activity for 14 days and Novozym 230 was active for over 6 months.

The correlation coefficients were determined by *Pearson's* method.

The comparison of data on the assay of fructans and fructose were analysed by linear regression. Both were calculated using a Systat 5.02 statistics programme.

## Results

Our initial experiments, based on the use of an endpoint determination of sorbitol generation, with an increased path length of 1250 seconds gave poor linearities above fructose concentrations of 250 mg/l in prepared standards, despite substantial increases in sorbitol dehydrogenase concentration. By shortening the path length considerably and reducing the sorbitol dehydrogenase to examine a reaction velocity-related absorbance change, after *Dalton & Turner* (5), we were able to obtain linear results up to 400 mg/l of fructose.

We found it necessary to augment the strength of the phosphate buffer to 500 mmol/l in order to reliably bring the pH of serum samples after dilution to near the optimal range for Novozym's chief components, pH 4.7 (12). As a corollary, HEPES buffer also needed to be considerably stronger, to subsequently elevate the pH to optimal for sorbitol dehydrogenase, at 7.4 (13).

Having used linear configuration inulin as a source for standards we were able to corroborate (6) a full and linear recovery of fructose from inulin. Allowing for a 6% impurity by weight of water and non-reducing sugars (Sigma quote 2–4% water content at time of manufacture), we found  $r = 0.999$ , linear regression  $y = 0.98x + 2.35$  mg/l, for standards from 0 to 400 mg/l in bovine serum albumin. In the presence of 50 mmol glucose in the samples, this correlation and regression was identical.

However on changing the source of our polyfructan to sinistrin, we found a consistent recovery of only 56% of the equivalent weight of fructose. Prolonging the incubation time to minimum of two hours at room temperature was sufficient to release 107% of the equivalent weight of crystalline fructose, just short of the 111.1% appropriate to hexose hydrolysis.

After a variety of experiments with enzyme combinations capable of levanase activity (2,6-polyfructan hy-

drolisis), we found that only a considerable excess of Novozym 230, was sufficient to maximally hydrolyse sinistrin in the desired preincubation time of 1250 s on the Mira. Comparison of our fructose yields by the assay with 24 h manual incubations of the same samples in plasma at 22 °C demonstrated near equivalent hydrolysis,  $y = 0.971x + 2.78$  mg/l ( $n = 70$ ). This was unchanged by further increasing the incubation concentration of Novozym to 67.5 kU/l.

After these modifications, our recovery of fructose from sinistrin against fructose standards, as analysed by linear regression was  $y = 1.067x + 0.05$  mg/l,  $r = 1.000$ , and in the presence of 54.3 mmol glucose standards, there appeared to be a minor effect on the greater concentrations of inulinase,  $y = 1.053x - 1.13$  mg/l,  $r = 1.000$ .

Interassay variation for whole clearance determination on the same set of samples was satisfactory, with CV at 4.4% (number of sample sets = 25, no of runs = 10). Following our prospectively determined practice of rejecting results with a greater than 10 mg/l variation between any duplicate samples, the CV for repeated clearance determinations was 2.8% ( $n = 19$ ). We have determined a range of infusion clearance values in 16 healthy volunteers of 112.9 ( $\pm$  standard deviation 16.8) ml/min, corrected for a surface area of 1.73 m<sup>2</sup>.

We confirmed that bovine serum albumin has a matrix effect in augmenting fructose recovery (6). With our assay this amounted to an additional 9%. This appears to be attributable in part to the sorbitol dehydrogenase conversion of fructose, standards prepared in bovine serum albumin consistently showed a 6% greater absorbance change compared to those in deionised water.

Finally we found that exposure of serum samples to 62 °C for 5 min was sufficient to inactivate sorbitol dehydrogenase, for sample preparation for patients whose serum was likely to contain substantial quantities of it, theoretically capable of altering the kinetics of the reaction. This mainly pertains in hepatocellular disease. This brief heating did not precipitate plasma proteins or detectably hydrolyse sinistrin.

## Discussion

Polyfructans are an abundant energy storage compound in plants, and the lack of a hydrolytic enzyme system in

mammals render them ideal as inert markers of renal clearance. The levanbiose (levans being  $\beta$ -2,6-linked polyfructans) side chains found in sinistrin augment the compound's solubility, but render it considerably less susceptible to exo- and endo-inulinase attack. Novozym's synergistic combination of 3 endoinulinases (EC 3.2.1.7), 5 exoinulinases (EC 3.2.1.80 and EC 3.2.1.26) with one enzyme of predominant invertase activity (also EC 3.2.1.26) (12, 14), is derived from *Aspergillus ficuum*. Some purified fungal exoinulinase and endoinulinases from another species of *Aspergillus* have been ineffective in cleaving levans (14, 15). Only more profligate varieties of exoinulinase, termed fructan  $\beta$ -fructosidases (EC 3.2.1.80) have levanase activity (14), and this seems to be an important discriminant in their classification. We found that a concentration 169 times greater than previously reported was necessary for maximal hydrolysis of sinistrin (6), and that description employed a 100-fold greater concentration than had been found necessary for the complete liberation of fructose from linear inulin up to 300 mg/l. Additionally we were obliged to include a prolonged incubation time, and considerably stronger buffers to ensure optimal pH for hydrolytic activity.

These observations underline the importance of ensuring the extent of sinistrin hydrolysis in enzymatic assays. A decrement in yield from incomplete hydrolysis might not be apparent if sinistrin standards were used as calibrators. Furthermore a differential decrement in fructose yields from plasma as opposed to urine or infusate samples, arising from a failure to adequately lower pH in samples with a stronger intrinsic buffering system could entail serious miscalculations of clearance.

Preliminary work suggests a very similar performance for Novo's currently available inulinase preparation Fructozyme, derived from *A. niger*.

## Acknowledgements

We wish to thank Professor *Christopher Pollock* and Dr *Neil Dalton* for theoretical and methodological guidance, Mr *Felix Xavier* for invaluable technical assistance, Novo Nordisk for repeated help with technical data and samples and Laevosan-Austria for technical data on Inutest<sup>TM</sup>, their preparation of sinistrin.

## References

1. Smith H. The Kidney: Structure and function in health and disease New York: Oxford University Press, 1976:231–8.
2. Heyrovsky A. A new method for the determination of inulin in plasma and urine. Clin Chim Acta 1956; 1:470–4.
3. Bergmeyer HU. Methods of enzymatic analysis New York, London: Academic Press, 1963:156.
4. Kuehnle H, Dahl K, Schmidt FH. Fully enzymatic inulin determination in small volume samples without deproteinization. Nephron 1992; 62:104–7.

5. Dalton N, Turner C. A sensitive and specific method for the measurement of inulin. *Ann Clin Biochem* 1987; 24 (1 Suppl), 24S.
6. Summerfield AL, Hortin GL, Smith CH, Wilhite TR, Landt M. Automated enzymatic analysis of inulin. *Clin Chem* 1993; 39:2333-7.
7. Wong ECC, Wilhite TR, Miller R, Smith C, Landt M. Less expensive enzymatic analysis for inulin with a kinetic assay [letter]. *Clin Chem* 1993; 40:1788-9.
8. Nitsch E, Iwanov W, Lederer K. Molecular characterisation of sinistrin. *Carb Res* 1979; 72:1-12.
9. Falbriard A, Favre H, Lucot G, Zender R. Polyfructosan, nouvelle substance glomerulaire utilisable en clinique courante. *Schweiz Med Wochenschr* 1969; 99:121-5.
10. Cole B, Giangiacomo J, Ingelfinger J, Robson AM. Measurement of renal function without urine collection. *N Engl J Med* 1972; 287:1109-14.
11. Schnurr E, Lahme W, Kupperts H. Measurement of renal clearance of inulin in the steady state without urine collection. *Clin Nephrol* 1980; 13:26-9.
12. Barrati J, Ettalbi M. Thermostable inulinases from *A. ficuum*. In: Fuchs A, editor. *Inulin and inulin-containing crops*. London: Elsevier Science Publishers, 1993:211-6.
13. Wilkinson JH. *Diagnostic enzymology*. UK: Edward Arnold, 1976.
14. Uchiyama T. Metabolism in microorganisms: biosynthesis and degradation of fructans. In: Suzuki M, editor. *Science and technology of fructans*. Boca Raton, Florida: CRC Press Inc, 1993: 169-77.
15. Uhm TB, Jeon DY, Byun SM, Hong JS, Groot Wasink JWD. Purification and properties of  $\beta$ -fructofuranosidase from *A. niger*. *Biochim Biophys Acta* 1987; 926:119-26.

Dr. C. P. R. Soper  
Chemical Pathology Dept.  
St Helier Hospital  
Wrythe Lane  
Carshalton  
Surrey SM5 1AA  
United Kingdom

